247 related articles for article (PubMed ID: 27996949)
1. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
[No Abstract] [Full Text] [Related]
2. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
3. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
[TBL] [Abstract][Full Text] [Related]
4. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR
Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340
[TBL] [Abstract][Full Text] [Related]
5. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
[TBL] [Abstract][Full Text] [Related]
6. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
[TBL] [Abstract][Full Text] [Related]
7. Icatibant as acute treatment for hereditary angioedema in adults.
Farkas H
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
[TBL] [Abstract][Full Text] [Related]
8. Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.
Grumach AS; Longhurst HJ; Aberer W; Bouillet L; Caballero T; Bygum A; Zanichelli A; Botha J; Andresen I; Maurer M;
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1078-1080. PubMed ID: 30170163
[No Abstract] [Full Text] [Related]
9. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
[TBL] [Abstract][Full Text] [Related]
10. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
[TBL] [Abstract][Full Text] [Related]
11. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study.
Javaud N; Gompel A; Bouillet L; Boccon-Gibod I; Cantin D; Smaiti N; Carpentier F; Boubaya M; Launay D; Adnet F; Fain O
Ann Allergy Asthma Immunol; 2015 Jun; 114(6):499-503. PubMed ID: 25935434
[TBL] [Abstract][Full Text] [Related]
16. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Cicardi M; Banerji A; Bracho F; Malbrán A; Rosenkranz B; Riedl M; Bork K; Lumry W; Aberer W; Bier H; Bas M; Greve J; Hoffmann TK; Farkas H; Reshef A; Ritchie B; Yang W; Grabbe J; Kivity S; Kreuz W; Levy RJ; Luger T; Obtulowicz K; Schmid-Grendelmeier P; Bull C; Sitkauskiene B; Smith WB; Toubi E; Werner S; Anné S; Björkander J; Bouillet L; Cillari E; Hurewitz D; Jacobson KW; Katelaris CH; Maurer M; Merk H; Bernstein JA; Feighery C; Floccard B; Gleich G; Hébert J; Kaatz M; Keith P; Kirkpatrick CH; Langton D; Martin L; Pichler C; Resnick D; Wombolt D; Fernández Romero DS; Zanichelli A; Arcoleo F; Knolle J; Kravec I; Dong L; Zimmermann J; Rosen K; Fan WT
N Engl J Med; 2010 Aug; 363(6):532-41. PubMed ID: 20818888
[TBL] [Abstract][Full Text] [Related]
17. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
18. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost.
Rasmussen ER; Aagaard L; Bygum A
Ann Allergy Asthma Immunol; 2016 May; 116(5):476-7. PubMed ID: 27017563
[No Abstract] [Full Text] [Related]
19. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
Wang Y; Jomphe C; Marier JF; Martin P
J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
